MedicalResearch.com: What is the background for this study? Would you describe the ReCET procedure? Response: Currently more than 400 million people worldwide have type 2 diabetes (T2D) and these numbers are rapidly increasing. At the moment there is no treatment option available that effectively treats the root cause of T2D, i.e. insulin resistance, the increasing loss of response to our body’s own insulin. T2D is generally treated with drug therapy, yet drug therapy can be expensive, requires the patient to take their drugs every day, and at best “controls” the disease without actually resolving it. Despite the availability of many…
Author: Abhay Panchal
Nonalcoholic fatty liver disease (NAFLD) results from fat accumulation within the liver and ranges from simple steatosis to steatohepatitis progressing to cirrhosis. NAFLD has become the most common cause of liver disease in the United States and Europe because of an aging population and increased prevalence of metabolic syndrome characterized by hypertension, hyperlipidemia, type 2 diabetes (T2DM), and central obesity.1 NAFLD is strongly associated with obesity and T2DM, where the prevalence of NAFLD in patients undergoing bariatric surgery exceeds 90% compared with an estimated prevalence of 25% in the general population.2 In patients with NAFLD, the estimated prevalence rates of…
A liquid biopsy assay that tests for only six circulating tumor DNA (ctDNA) methylation markers has shown high accuracy in identifying the risk for relapse among patients with colorectal cancer (CRC). Patients who were ctDNA methylation positive 1 month after surgery were 17.5 times more likely to relapse, compared with ctDNA-negative patients. And following adjuvant chemotherapy, ctDNA-positive patients had a significantly shorter recurrence-free survival than their ctDNA-negative peers. Overall, “we found that ctDNA methylation was the most significant prognostic factor for recurrence-free survival among all clinicopathologic risk factors on multivariable analysis,” the authors, led by Shaobo Mo, MD, Fudan University…
CAMBRIDGE, Mass. & MINNEAPOLIS–(BUSINESS WIRE)–Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, and Provation, the premier software and SaaS provider of clinical productivity and workflow automation solutions and a wholly-owned operating company of Fortive Corporation (NYSE: FTV), announced today the upcoming commercial availability of SKOUT, real-time artificial intelligence for polyp detection, in the second quarter of 2023. SKOUT is indicated as a computer-aided detection tool to assist qualified and trained endoscopists in identifying potential colorectal polyps during colonoscopy examinations in adult patients undergoing colorectal cancer screening or surveillance. Colorectal cancer is the second leading cause of cancer-related deaths in…
Researchers Seek To Identify and Establish New Standards of Care PALO ALTO, CA / ACCESSWIRE / May 2, 2023 / Lynx.MD, a leading medical data intelligence platform, today announced a new partnership with Prometheus Laboratories Inc. (“Prometheus”) and Gastro Health to securely unite real-world clinical data for retrospective analysis of inflammatory bowel disease (IBD) biologic treatment. The partnership will bring together 10-years of de-identified IBD clinical laboratory data and patient data, using the Lynx Trusted Data Environment, to research and demonstrate the value of the Prometheus Anser® IFX therapeutic drug monitoring test to improve patient clinical outcomes and reduce overall…
CHICAGO, May 3, 2023 (Newswire.com) – Sifter SP, Inc. and Ayble Health, Inc. have entered a partnership to integrate Sifter’s innovative Shop By Diet technology and enhanced food and nutrition data into Ayble’s precision nutrition program. This partnership provides Ayble members an unprecedented level of dietary support for Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), and other chronic digestive conditions. It’s all about diet personalization: one size fits none. Ayble’s HIPAA-compliant digital gastroenterology care platform, powered by Sifter technology, combines behavior science and clinical protocols to radically improve the standard of care for IBS/IBD patients.
UnitedHealthcare recently announced that beginning June 1, 2023, commercial plan members will be required to obtain prior authorization for gastroenterology endoscopy services. By far the largest health insurance company in the United States, UnitedHealthcare generates more than $286 billion in total revenue — more than double that of the next closest competition, Anthem —and serves approximately 26.7 million Americans.
The last 10 years have been a time of tremendous change in U.S. healthcare. One of the key drivers of this change has been growing investment from private equity into both larger healthcare companies and, more recently, into specialty medical practices. Although this activity is reported on and sometimes scrutinized, less often is any focus given to the positive impact that this inflow of capital has had, both for doctors and patients. According to public reports, private equity acquisitions of healthcare-related businesses have risen from an estimated annual deal value of $41.5 billion in 2010 to more than $200 billion…
DALLAS, May 2, 2023 /PRNewswire/ — GI Alliance, the nation’s premier gastroenterology management company, and the American Society for Gastrointestinal Endoscopy (ASGE) are pleased to announce a new group partnership where all providers of GI Alliance are ASGE members. With the launch of this new institutional membership category, GI Alliance has become ASGE’s first group member with the joint goal of advancing the practice of GI. GI Alliance’s provider team includes 785 physicians and 851 advanced practice providers (APPs), all of whom will benefit from the comprehensive membership privileges offered by ASGE. These benefits include cutting-edge education and training, pertinent…
DENVER–(BUSINESS WIRE)–EvoEndo®, Inc. (“EvoEndo”), a medical device company developing platforms for Unsedated Transnasal Endoscopy (TNE), announced that the company received an investment from the American Gastroenterological Association’s (AGA) new venture capital fund, GI Opportunity Fund 1. “AGA is proud to support EvoEndo® and its innovative technology that has the potential to improve care, save time, resources, and cost for hospitals and the GI community at large,” said Michael L. Kochman, MD, AGAF, MASGE, Wilmott Family Professor of Medicine and Surgery, Center for Endoscopic Innovation, Research and Training, Gastroenterology Division, University of Pennsylvania Health System; Fund Manager and Advisor, AGA GI…